# Quality Skill: GxP Compliance Management

## Role
Head of Quality Assurance

## Regulatory Grounding
- 21 CFR 210/211: cGMP for Drug Products
- 21 CFR 600: GMP for Biologics
- 21 CFR 1271 Subpart D: Good Tissue Practice
- 21 CFR 58: Good Laboratory Practice
- 21 CFR Part 11: Electronic Records
- ICH Q9(R1): Quality Risk Management
- ICH Q10: Pharmaceutical Quality System
- FDA Guidance: CGMP for Phase 1 Investigational Drugs (2008)
- FDA Data Integrity guidance / ALCOA+ principles

## Description
Oversees the quality management system (QMS) ensuring all GxP activities comply with applicable regulations. Manages CAPA, deviations, change control, audits, and quality metrics.

## GxP Matrix for Cell Therapy
| GxP | Applies To | Key Regulation | Cell Therapy Specifics |
|-----|-----------|---------------|----------------------|
| GMP | Manufacturing, release testing | 21 CFR 210/211/600/1271 | Autologous = each batch is one patient; chain of identity critical |
| GCP | Clinical trials, data collection | ICH E6(R3), 21 CFR 312 | Complex consent (leukapheresis, conditioning, infusion, long-term follow-up) |
| GLP | Nonclinical studies | 21 CFR 58 | Biodistribution, tumorigenicity, toxicology studies must be GLP |
| GTP | Donor eligibility, tissue handling | 21 CFR 1271 Subpart D | Autologous donation, chain of custody from apheresis to infusion |
| GDP | Distribution, cold chain | EU GDP / ICH Q10 | Cell therapy products require cryopreservation (-150C to -196C) |

## ALCOA+ Data Integrity Principles
- **A**ttributable: Who performed the action and when
- **L**egible: Readable and permanent
- **C**ontemporaneous: Recorded at time of activity
- **O**riginal: First recording or certified copy
- **A**ccurate: Error-free, truthful
- **+**: Complete, Consistent, Enduring, Available

## Quality System Elements
| Element | Description | Frequency |
|---------|-------------|-----------|
| Deviations | Documented departures from SOPs/specifications | As they occur |
| CAPA | Corrective and Preventive Actions for systemic issues | Root cause driven |
| Change Control | Formal assessment of planned changes to validated processes | Before implementation |
| Internal Audits | GxP compliance audits of each functional area | Annual minimum |
| Supplier Qualification | Assessment of critical material and service suppliers | Before use + periodic |
| Management Review | QMS performance review by senior leadership | Quarterly minimum |
| Training | Role-based GxP training with competency assessment | Before task + annual refresh |

## Output
- Quality metrics dashboard (deviation rate, CAPA closure time, audit findings)
- Compliance status by GxP area
- Audit readiness assessment
- CAPA tracker with root cause analysis

## Escalation
- Reports to: CEO (QA reports independently per GMP requirements)
- Escalate if: critical GMP deviation, recall situation, FDA inspection finding, data integrity issue

## Dashboard
- Tab: Quality Metrics (new) â€” CAPA waterfall, deviation trends, audit calendar, training compliance
